Skip to content

Alkermes ALKS Accounts payable and other current liabilities (Note 11)

Accounts payable and other current liabilities (Note 11) at other companies

AbbVie logo
AbbVieABBV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Royalty Pharma logo
Royalty PharmaRPRX
TG Therapeutics logo
TG TherapeuticsTGTX

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's accounts payable and other current liabilities (note 11).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's accounts payable and other current liabilities (note 11)?
Alkermes (ALKS) reported accounts payable and other current liabilities (note 11) of $292.58M in Q1 2026.
How has Alkermes's accounts payable and other current liabilities (note 11) changed year-over-year?
Alkermes's accounts payable and other current liabilities (note 11) increased by 57.3% year-over-year, from $186.04M to $292.58M.
What is the long-term trend for Alkermes's accounts payable and other current liabilities (note 11)?
Over 5 years (2020 to 2025), Alkermes's accounts payable and other current liabilities (note 11) has grown at a -6.8% compound annual growth rate (CAGR), from $412.17M to $289.57M.